Nova lite

Manufactured by Inova Diagnostics

NOVA Lite is a compact and automated laboratory instrument designed for the detection and measurement of specific analytes in biological samples. The core function of the NOVA Lite is to perform immunoassay-based testing, providing accurate and reliable results for clinical diagnostic purposes.

Automatically generated - may contain errors

Lab products found in correlation

Quanta lite, by Inova Diagnostics (2 mentions) Phadia 250 platform, by Thermo Fisher Scientific (1 mentions) Bio flash, by Inova Diagnostics (1 mentions)

2 protocols using nova lite

Comprehensive Autoimmune Biomarker Panel Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

For autoimmune biomarker analysis, frozen plasma was shipped on dry ice to Exagen, Inc., which has a clinical laboratory accredited by the College of American Pathologists and certified under the Clinical Laboratory Improvement Amendments. Thawed plasma was aliquoted and distributed for the following tests: antinuclear antibodies (ANA) were measured using enzyme-linked immunosorbent assays (ELISA) (QUANTA Lite; Inova Diagnostics) and indirect immunofluorescence (IFA) (NOVA Lite; Inova Diagnostics); anti-dsDNA antibodies were also measured by ELISA and were confirmed by IFA with Crithidia luciliae; extractable nuclear antigen autoantibodies (anti-Sm, anti-SS-B/La IgG, anti-Scl-70 IgG, anti-U1RNP IgG, anti-RNP70 IgG, anti-CENP IgG, anti-Jo-1 IgG and anti-CCP IgG) as well as RF IgA and IgM were measured using the EliA test on the Phadia 250 platform (ThermoFisher Scientific); IgG, IgM and IgA isotypes of anticardiolipin and anti-β2‐glycoprotein, as well as anti-Ro52, anti-Ro60, anti-GBM, anti-PR3 and anti-MPO, were measured using a chemiluminescence immunoassay (BIO-FLASH; Inova Diagnostics); anti-CarP, anti-RNA-pol-III, and the IgG and IgM isotypes of anti-PS/PT were measured by ELISA (QUANTA Lite; Inova Diagnostics), whereas C-ANCA and P-ANCA were measured by IFA (NOVA Lite; Inova Diagnostics). All assays were performed following the manufacturer’s instructions.

Woodruff M.C., Ramonell R.P., Haddad N.S., Anam F.A., Rudolph M.E., Walker T.A., Truong A.D., Dixit A.N., Han J.E., Cabrera-Mora M., Runnstrom M.C., Bugrovsky R., Hom J., Connolly E.C., Albizua I., Javia V., Cashman K.S., Nguyen D.C., Kyu S., Singh Saini A., Piazza M., Tipton C.M., Khosroshahi A., Gibson G., Martin G.S., Maier C.L., Esper A., Jenks S.A., Lee F.E, & Sanz I. (2022). Dysregulated naive B cells and de novo autoreactivity in severe COVID-19. Nature, 611(7934), 139-147.

+ Open protocol

+ Expand

Complement Activation and Autoantibody Profiling

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Serum C3 and C4 were determined by immunoturbidimetry (The Binding Site, San Diego, California, USA)11 (link) and were considered low if below the manufacturer’s lower limits of normal (81.1 and 12.9 mg/dL for C3 and C4, respectively). Low complement status refers to low C3 and/or low C4.
Complement activation was determined using CB-CAPs measured by quantitative flow cytometry.11 (link) CB-CAPs were considered abnormal if levels of EC4d and/or BC4d were above the 99th percentile of a group of healthy individuals (>14 and >60 net mean fluorescence intensity, respectively).7 8 11 (link) Abnormal CB-CAPs status refers to abnormal EC4d and/or abnormal BC4d.
Anti-double-stranded DNA (dsDNA) antibodies were determined by ELISA (Quanta Lite, Inova Diagnostics, San Diego, California, USA). All serum samples above 301 IU/mL were further tested by indirect immunofluorescence assay (IFA) using the Crithidia luciliae assay (Nova-Lite, Inova Diagnostics). Anti-dsDNA antibodies were considered positive if confirmed by IFA.

Arriens C., Alexander R.V., Narain S., Saxena A., Collins C.E., Wallace D.J., Massarotti E., Conklin J., Kalunian K.C., Putterman C., Ramsey-Goldman R., Buyon J.P., Askanase A., Furie R.A., James J.A., Bello G.A., Manzi S., Ahearn J., O'Malley T., Weinstein A, & Dervieux T. (2020). Cell-bound complement activation products associate with lupus severity in SLE. Lupus Science & Medicine, 7(1), e000377.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!